Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Study ID
- NCT00370539
- Phase
- PHASE3
- Status
- Unknown
Conditions
- Neovascular Age-Related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
Study Details
To compare the efficacy and safety of photodynamic therapy (PDT) combined with intravitreal bevacizumab versus combination of photodynamic therapy , intravitreal bevacizumab and intravitreal triamcinolone for neovascular AMD.
Key Dates
- Start date
- Sep 30, 2006
- Status verified
- Nov 2006
- Completion
- Nov 30, 2006
Study Design
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
Visual acuity
Central Contacts
- Hamid Ahmadieh, MD+98 21 22585952
Related Studies
- Extension Study for the Port Delivery System With Ranibizumab (Portal)PHASE3 · Recruiting · Hoffmann-La Roche · Phoenix, Arizona
- Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyPHASE2 · Enrolling By Invitation · AbbVie · Phoenix, Arizona
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)PHASE4 · Recruiting · Genentech, Inc. · Mesa, Arizona
- Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMDPHASE3 · Recruiting · Jaeb Center for Health Research · Glendale, California